Erratum to: Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: A randomized controlled trial (Indian Pediatr., (2017), 54, (279-83), 10.1007/s13312-017-1088-0)

M. Shivakumar, P. Jayashree, Muhammad Najih, Leslie Edward Simon Lewis, Y. Ramesh Bhat, Asha Kamath, Shashikala

Research output: Contribution to journalComment/debate

Abstract

In Table II, P value in first row (against ‘continuing apnea’ at 1–3 d of therapy) should be 0.05 in place of 0.03; and in second row (against ‘continuing apnea’ at 4–7 d of therapy), P value should be 0.03 in place of 0.05. In Fig. 1, the number in the frame “Neonates completed treatment and follow-up” in the Caffeine group should be read as 77 in place of 79; and in the Aminophylline group, it should be 79 in place of 77.

Original languageEnglish
Number of pages1
JournalIndian Pediatrics
Volume54
Issue number10
DOIs
Publication statusPublished - 01-10-2017

Fingerprint

Aminophylline
Apnea
Caffeine
Randomized Controlled Trials
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{b9f24f79cdd645a7b98ac1697da445b3,
title = "Erratum to: Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: A randomized controlled trial (Indian Pediatr., (2017), 54, (279-83), 10.1007/s13312-017-1088-0)",
abstract = "In Table II, P value in first row (against ‘continuing apnea’ at 1–3 d of therapy) should be 0.05 in place of 0.03; and in second row (against ‘continuing apnea’ at 4–7 d of therapy), P value should be 0.03 in place of 0.05. In Fig. 1, the number in the frame “Neonates completed treatment and follow-up” in the Caffeine group should be read as 77 in place of 79; and in the Aminophylline group, it should be 79 in place of 77.",
author = "M. Shivakumar and P. Jayashree and Muhammad Najih and Lewis, {Leslie Edward Simon} and {Ramesh Bhat}, Y. and Asha Kamath and Shashikala",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s13312-017-1160-9",
language = "English",
volume = "54",
journal = "Indian Pediatrics",
issn = "0019-6061",
publisher = "Springer India",
number = "10",

}

TY - JOUR

T1 - Erratum to

T2 - Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: A randomized controlled trial (Indian Pediatr., (2017), 54, (279-83), 10.1007/s13312-017-1088-0)

AU - Shivakumar, M.

AU - Jayashree, P.

AU - Najih, Muhammad

AU - Lewis, Leslie Edward Simon

AU - Ramesh Bhat, Y.

AU - Kamath, Asha

AU - Shashikala,

PY - 2017/10/1

Y1 - 2017/10/1

N2 - In Table II, P value in first row (against ‘continuing apnea’ at 1–3 d of therapy) should be 0.05 in place of 0.03; and in second row (against ‘continuing apnea’ at 4–7 d of therapy), P value should be 0.03 in place of 0.05. In Fig. 1, the number in the frame “Neonates completed treatment and follow-up” in the Caffeine group should be read as 77 in place of 79; and in the Aminophylline group, it should be 79 in place of 77.

AB - In Table II, P value in first row (against ‘continuing apnea’ at 1–3 d of therapy) should be 0.05 in place of 0.03; and in second row (against ‘continuing apnea’ at 4–7 d of therapy), P value should be 0.03 in place of 0.05. In Fig. 1, the number in the frame “Neonates completed treatment and follow-up” in the Caffeine group should be read as 77 in place of 79; and in the Aminophylline group, it should be 79 in place of 77.

UR - http://www.scopus.com/inward/record.url?scp=85032265300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032265300&partnerID=8YFLogxK

U2 - 10.1007/s13312-017-1160-9

DO - 10.1007/s13312-017-1160-9

M3 - Comment/debate

AN - SCOPUS:85032265300

VL - 54

JO - Indian Pediatrics

JF - Indian Pediatrics

SN - 0019-6061

IS - 10

ER -